GlassScriptPhysician profile
Michael H Winkelman
NPI 1740373448
$1,924.23
in general payments reported to CMS, 2019-2025
26 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $149 · 2021: $272 · 2022: $296 · 2023: $288 · 2024: $332 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $808.40 | 2022-2025 | Botox, Ubrelvy |
| Allergan, INC. | $266.06 | 2019-2022 | |
| Eisai INC. | $97.69 | 2020-2021 | |
| Piramal Critical Care | $72.23 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $68.76 | 2022-2023 | Hetlioz, Fanapt |
| Scilex Pharmaceuticals INC. | $61.77 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.03 | 2022 | |
| Pfizer INC. | $53.44 | 2025 | |
| Daiichi Sankyo INC. | $53.16 | 2019 | |
| Merz Pharmaceuticals, LLC | $50.47 | 2024 | Xeomin |
| Idorsia Pharmaceuticals US INC | $43.38 | 2023-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $38.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $32.40 | 2019-2020 | |
| Medline Industries LP | $26.63 | 2019-2022 | |
| Lundbeck LLC | $21.67 | 2025 | Vyepti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.49 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.12 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.48 | 2025 | |
| Ibsa Pharma INC. | $16.18 | 2023 | Tirosint, Licart |
| Arbor Pharmaceuticals, INC. | $15.78 | 2021 | |
| Mdd US Operations, LLC | $15.47 | 2022 | |
| Grt US Holding, INC. | $15.28 | 2022 | |
| Biodelivery Sciences International, INC. | $14.48 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.37 | 2021 | |
| Strongbridge US INC. | $12.42 | 2019 | |
| Lilly USA, LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Winkelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.